Welcome to our dedicated page for Kneat Com news (Ticker: KSIOF), a resource for investors and traders seeking the latest updates and insights on Kneat Com stock.
Kneat Com (OTCQX: KSIOF) provides mission-critical digital validation solutions for pharmaceutical, biotechnology, and medical device industries through its Kneat Gx platform. This page aggregates official press releases, regulatory updates, and strategic developments from the company, serving as a centralized hub for tracking its innovation in compliance automation.
Investors and industry professionals will find timely updates on product enhancements, partnership announcements, and operational milestones. Content spans earnings reports, technology certifications, and client success stories relevant to highly regulated sectors. All materials are sourced directly from company communications to ensure accuracy and compliance with financial disclosure standards.
The curated collection enables users to monitor Kneat Com's progress in reducing validation cycle times, expanding global operations, and maintaining ISO/21 CFR compliance. Regular updates provide insights into how the company addresses evolving regulatory requirements across 60+ countries through its SaaS platform.
Bookmark this page for streamlined access to Kneat Com's latest announcements, or check back regularly to stay informed about developments impacting digital validation practices in life sciences and adjacent industries.
Kneat (OTC: KSIOF), a company specializing in digitizing and automating validation and quality processes, has scheduled its Q2 2025 financial results release for August 5, 2025 after TSX market close.
The company will host a conference call and Q&A session for analysts on August 6, 2025 at 09:00 ET. CEO Eddie Ryan and CFO Dave O'Reilly, along with outgoing CFO Hugh Kavanagh, will lead the webcast presentation. The financial results will be accessible through the company's investor relations website.
Kneat (OTCQC: KSIOF), a leader in digitizing and automating validation and quality processes, has announced a significant leadership transition. CFO Hugh Kavanagh will retire from the company, with his final day set for August 8th, 2025.
The company has appointed Dave O'Reilly as the new CFO, effective July 7th, 2025. O'Reilly brings substantial experience from his previous role as CFO at Ekco, where he helped scale the company to $200 million in annual revenue. His background includes serving as international controller for a $4 billion-SaaS business, Consensus Cloud Solutions/Ziff Davis Inc.
To ensure continuity, Kavanagh and O'Reilly will work together for a one-month transition period. CEO Eddie Ryan expressed confidence in O'Reilly's ability to contribute to Kneat's continued scaling efforts in the Life Sciences sector.
Kneat (OTCQC: KSIOF) has secured a multi-year Master Services Agreement with a major U.S.-based healthcare technology and diagnostics company. The unnamed company, which employs over 50,000 people and operates manufacturing facilities in more than a dozen countries, will implement Kneat's Gx platform to digitize their Commissioning, Qualification and Validation workflows.
The platform will be deployed at several lead manufacturing sites, focusing on facilities, equipment, and computer systems validation. According to the State of Validation 2025 study, 93% of organizations are now using or planning to use digital validation, up from 86% in 2024.
Kneat (TSX: KSI) (OTC: KSIOF), a company specializing in digitizing and automating validation processes, held its Annual General Meeting (AGM) on May 28, 2025. At the meeting, shareholders voted on two main items: the election of directors and the re-appointment of auditors.
All five nominated directors were successfully elected to the board with strong approval ratings ranging from 96.02% to 100%. Edmund Ryan received unanimous support (100%), while Carol Leaman (99.97%), Nutan Behki (97.32%), Ian Ainsworth (97.27%), and Wade K. Dawe (96.02%) also received overwhelming approval.
Additionally, shareholders approved the re-appointment of KPMG LLP as the company's auditors with 99.91% of votes in favor.
Kneat, a leader in validation and quality process digitization, will release its Q1 2025 financial results on May 7, 2025, after TSX market close. The company has scheduled a conference call and Q&A session for sell-side analysts on May 8, 2025, at 09:00 ET (14:00 GMT).
Key details:
- Earnings Release Date: May 7, 2025 (post-market)
- Conference Call Date: May 8, 2025
- Time: 09:00 ET / 14:00 GMT
- Presenters: Eddie Ryan (CEO) and Hugh Kavanagh (CFO)
Investors can access the financial results through the Financial Information section on Kneat's website. A registration link is available for the live webcast of the analyst call.
Kneat (KSIOF) has secured a Services Agreement with a major European-based multinational generic pharmaceuticals manufacturer to digitalize its drawing management process. The unnamed client, with over 20,000 employees and operations in more than 100 countries, will initially implement Kneat's platform at its largest European manufacturing facility.
The drawing management system will support engineering and validation processes by digitalizing technical drawings, eliminating paper-based errors, maintaining revision traceability, and controlling access. The client has the potential to expand Kneat's usage to streamline all validation workflows across their operations.
Kneat reports strong performance metrics, including a 151% net revenue retention rate as of December 31, 2024, and a 97% customer satisfaction rate rating their support as 'very good' or 'excellent'. The company serves the majority of the top 20 largest life sciences companies globally.
Kneat (KSIOF) reported strong financial results for Q4 and full year 2024, with significant growth across key metrics. Total revenue reached $13.7 million in Q4 2024, up 40% year-over-year, while SaaS revenue grew 41% to $12.5 million.
The company achieved notable improvements in profitability, with Q4 2024 gross profit increasing 48% to $10.4 million and gross margin reaching 75%. Annual Recurring Revenue (ARR) grew 60% to $59.7 million, and the company maintained a strong Net Revenue Retention Rate of 151%.
Throughout 2024, Kneat added five large strategic customers and strengthened its partner program with additions like Körber and ALTEN Group. The company completed two equity financings, raising aggregate gross proceeds of $55.6 million. In early 2025, Kneat announced new partnerships, including with Capgemini, and secured additional customer wins in the specialty therapeutics and consumer products sectors.